Beijing Hotgen Biotech Co., Ltd. (Hotgen Biotech, stock code: 688068) was founded in June 2005 as a high-tech enterprise focusing on the research & development, and manufacture of in-vitro diagnostics (IVD) medical equipment and antibody biomedicine.

After years of research, Hotgen Biotech has developed 8 major technology platforms, such as In Vitro diagnostic reagent bioactive raw material development platform, glycoprotein capture technical platform, magnetic particles chemiluminescence, up-converting phosphor, and colloidal gold-based immunoassay. These technology platforms form a closed-loop system for in-vitro diagnostic R&D and production.

Hotgen Biotech has established a complete serie of immunodiagnostic platform, from high-precision up-converting phosphor POCT (UPT series), low-to high-throughput single-cartridge chemiluminescence platforms (MQ60 series), to large-scale fully automatic chemiluminescence platform (C2000), which facilitates the application of the immunodiagnostic platform in various diagnostic scenarios. Hotgen Biotech’s products are widely used in the clinical and public safety fields. The specific users include not only hospitals, clinics, and third-party testing labs at all levels, but also disaster response units, customs, and food and feed enterprises.